Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer

Siegel, 2020, Cancer statistics, 2020, CA A Cancer J. Clin., 70, 7, 10.3322/caac.21590 Oualla, 2017, Novel therapeutic strategies in the treatment of triple-negative breast cancer, Thera. Adv. Med. Oncol., 9, 493, 10.1177/1758834017711380 Lehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest., 121, 2750, 10.1172/JCI45014 Dent, 2007, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin. Canc. Res., 13, 4429, 10.1158/1078-0432.CCR-06-3045 Freedman, 2009, Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation, Cancer, 115, 946, 10.1002/cncr.24094 Voduc, 2010, Breast cancer subtypes and the risk of local and regional relapse, J. Clin. Oncol., 28, 1684, 10.1200/JCO.2009.24.9284 Kennecke, 2010, Metastatic behavior of breast cancer subtypes, J. Clin. Oncol., 28, 3271, 10.1200/JCO.2009.25.9820 Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol., 26, 1275, 10.1200/JCO.2007.14.4147 Gluz, 2008, Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial, Ann. Oncol., 19, 861, 10.1093/annonc/mdm551 Bendell, 2003, Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma, Cancer, 97, 2972, 10.1002/cncr.11436 Leone, 2015, Breast cancer brain metastases: the last frontier, Exp. Hematol. Oncol., 4, 33, 10.1186/s40164-015-0028-8 Adkins, 2016, Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer, Clin. Exp. Metastasis, 33, 373, 10.1007/s10585-016-9784-z Ranjan, 2017, Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer, Tumour Biol., 39, 10.1177/1010428317705517 Ranjan, 2017, Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1, Oncotarget, 8, 32960, 10.18632/oncotarget.16515 Wu, 2014, Anti-tumor effects of penfluridol through dysregulation of cholesterol homeostasis, Asian Pac. J. Cancer Prev. APJCP, 15, 489, 10.7314/APJCP.2014.15.1.489 Hedrick, 2017, Penfluridol represses integrin expression in breast cancer through induction of reactive oxygen species and downregulation of sp transcription factors, Mol. Canc. Therapeut., 16, 205, 10.1158/1535-7163.MCT-16-0451 Ranjan, 2016, Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast cancer by inhibiting integrin signaling Axis, Canc. Res., 76, 877, 10.1158/0008-5472.CAN-15-1233 Shaw, 2019, Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy, Semin. Cancer Biol. Tuan, 2019, Penfluridol as a candidate of drug repurposing for anticancer agent, Molecules, 24, 10.3390/molecules24203659 Ashraf-Uz-Zaman, 2018, Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity, Bioorg. Med. Chem. Lett, 28, 3652, 10.1016/j.bmcl.2018.10.036 Nair, 2016, A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm., 7, 27, 10.4103/0976-0105.177703 Wang, 1982, Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia, J. Clin. Pharmacol., 22, 236, 10.1002/j.1552-4604.1982.tb02667.x Chouinard, 1976, Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit, Am. J. Psychiatr., 133, 850, 10.1176/ajp.133.7.850 Jackson, 1975, The effect of long-term penfluridol treatment on the sensitivity of the dopamine receptors in the nucleus accumbens and in the corpus striatum, Psychopharmacologia, 45, 151, 10.1007/BF00429053 Ota, 1974, Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent, J. Clin. Pharmacol., 14, 202, 10.1002/j.1552-4604.1974.tb01398.x Chen, 2011, Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers, Bioorg. Med. Chem. Lett, 21, 234, 10.1016/j.bmcl.2010.11.029 Ananda Kumar, 2009, Synthesis and in vitro antiproliferative activity of novel 1-benzhydrylpiperazine derivatives against human cancer cell lines, Eur. J. Med. Chem., 44, 1223, 10.1016/j.ejmech.2008.09.025 Cramer, 2004, Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities, J. Med. Chem., 47, 6777, 10.1021/jm049501b Cramer, 1999, Prospective identification of biologically active structures by topomer shape similarity searching, J. Med. Chem., 42, 3919, 10.1021/jm990159q Sun, 2012, Classification of scaffold-hopping approaches, Drug Discov. Today, 17, 310, 10.1016/j.drudis.2011.10.024 Mauser, 2008, Recent developments in de novo design and scaffold hopping, Curr. Opin. Drug Discov. Dev, 11, 365 1976, Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit, Am. J. Psychiatr., 133, 850, 10.1176/ajp.133.7.850 Ota, 1974, Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent, J. Clin. Pharmacol., 14, 202, 10.1002/j.1552-4604.1974.tb01398.x Dale, 2016, Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function, CNS Spectr., 21, 143, 10.1017/S1092852915000425 Al Shoyaib, 2019, Intraperitoneal route of drug administration: should it Be used in experimental animal studies?, Pharmaceut. Res., 37, 10.1007/s11095-019-2745-x Airoldi, 1974, Distribution of penfluridol in rats and mice, Eur. J. Pharmacol., 25, 291, 10.1016/0014-2999(74)90257-X Bouillot Anne Marie, 2010 Wang, 2009, Novel meso-substituted porphyrins: synthesis, characterization and photocatalytic activity of their TiO2-based composites, Dyes Pigments, 80, 321, 10.1016/j.dyepig.2008.08.008 Chen, 2012 Hassib, 2019, Synthesis and biological evaluation of new prodrugs of etodolac and tolfenamic acid with reduced ulcerogenic potential, Eur. J. Pharmaceut. Sci., 140 Carlsen, 1996, Synthesis of benzylidene-protected dihydroxyacetone, Acta Chem. Scand., 50, 185, 10.3891/acta.chem.scand.50-0185 Jurayi, 2003 Dorel, 2019, The buchwald–hartwig amination after 25 Years, Angew. Chem. Int. Ed., 58, 17118, 10.1002/anie.201904795 Cao, 2004, Novel azido and isothiocyanato analogues of [3-(4-phenylalkylpiperazin-1-yl)propyl]bis(4-fluorophenyl)amines as potential irreversible ligands for the dopamine transporter, J. Med. Chem., 47, 6128, 10.1021/jm049670w Xiang, 2008, Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model, J. Med. Chem., 51, 4068, 10.1021/jm8004948 Appel, 1975, Tertiary phosphane/tetrachloromethane, a versatile reagent for chlorination, dehydration, and P?N linkage, Angew Chem. Int. Ed. Engl., 14, 801, 10.1002/anie.197508011 Davis, 1978, The Nitration of alkylbenzenes: a lecture demonstration, J. Chem. Educ., 55, 10.1021/ed055p34.1 Esteves, 2003, Unified mechanistic concept of electrophilic aromatic nitration: convergence of computational results and experimental data, J. Am. Chem. Soc., 125, 4836, 10.1021/ja021307w Benati, 2006, Radical reduction of aromatic azides to amines with triethylsilane, J. Org. Chem., 71, 5822, 10.1021/jo060824k Saito, 2008, C8-alkynyl- and alkylamino substituted 2′-deoxyguanosines: a universal linker for nucleic acids modification, Tetrahedron, 64, 3578, 10.1016/j.tet.2008.01.091 Liu, 2013, Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors, Bioorg. Med. Chem., 21, 2960, 10.1016/j.bmc.2013.03.075 Chen, 2016, Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents, Eur. J. Med. Chem., 107, 12, 10.1016/j.ejmech.2015.10.045 Yadagiri, 2014, Rational design, synthesis and anti-proliferative evaluation of novel benzosuberone tethered with hydrazide-hydrazones, Bioorg. Med. Chem. Lett, 24, 5041, 10.1016/j.bmcl.2014.09.018 Brough, 2017, Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase, J. Med. Chem., 60, 2271, 10.1021/acs.jmedchem.6b01478 Chayah, 2016, N,N′-Disubstituted thiourea and urea derivatives: design, synthesis, docking studies and biological evaluation against nitric oxide synthase, Med. Chem. Comm., 7, 667, 10.1039/C5MD00477B Ponzano, 2014, Synthesis, biological evaluation, and 3D QSAR study of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters as N-acylethanolamine acid amidase (NAAA) inhibitors, J. Med. Chem., 57, 10101, 10.1021/jm501455s Sumita, 2014, Acid-promoted chemoselective introduction of amide functionality onto aromatic compounds mediated by an isocyanate cation generated from carbamate, Chem. Asian J., 9, 2995, 10.1002/asia.201402625 Manickam, 2018, Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator, Eur. J. Med. Chem., 143, 1869, 10.1016/j.ejmech.2017.10.077 De Luca, 2003, Trichloroisocyanuric/TEMPO oxidation of alcohols under mild conditions: a close investigation, J. Org. Chem., 68, 4999, 10.1021/jo034276b Winterton, 2018, Discovery of cytochrome P450 4F11 activated inhibitors of stearoyl coenzyme A desaturase, J. Med. Chem., 61, 5199, 10.1021/acs.jmedchem.8b00052 Walsh, 1989, Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-((aryloxy)propyl)piperidines and structurally related compounds, J. Med. Chem., 32, 105, 10.1021/jm00121a022 Sander, 2015, Development of fluorine-18 labeled metabolically activated tracers for imaging of drug efflux transporters with positron emission tomography, J. Med. Chem., 58, 6058, 10.1021/acs.jmedchem.5b00652 Ghosh, 2020, Urea derivatives in modern drug discovery and medicinal chemistry, J. Med. Chem., 63, 2751, 10.1021/acs.jmedchem.9b01541 Perez-Garcia, 2018, Targeting FGFR pathway in breast cancer, Breast, 37, 126, 10.1016/j.breast.2017.10.014 Lehmann, 2014, Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes, J. Pathol., 232, 142, 10.1002/path.4280 Lee, 2014, Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets, Ann. Surg Oncol., 21, 1561, 10.1245/s10434-013-3456-x Sharpe, 2011, FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo, Clin. Canc. Res., 17, 5275, 10.1158/1078-0432.CCR-10-2727 De Luca, 2017, FGFR-targeted therapeutics for the treatment of breast cancer, Expet Opin. Invest. Drugs, 26, 303, 10.1080/13543784.2017.1287173 Tucker, 2014, Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4, Structure, 22, 1764, 10.1016/j.str.2014.09.019 Wang, 2017, Synthesis and antineoplastic evaluation of mitochondrial complex II (succinate dehydrogenase) inhibitors derived from atpenin A5, ChemMedChem, 12, 1033, 10.1002/cmdc.201700196 Slack, 2020, Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinyl alkyl alicyclic amines at the dopamine transporter: functionalizing the terminal nitrogen affects affinity, selectivity, and metabolic stability, J. Med. Chem., 63, 2343, 10.1021/acs.jmedchem.9b01188 Di, 2003, Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates, J. Biomol. Screen, 8, 453, 10.1177/1087057103255988 Bera, 2016, In vitro metabolic stability and permeability of gymnemagenin and its in vivo pharmacokinetic correlation in rats - a pilot study, Planta Med., 82, 544, 10.1055/s-0042-101032 Alden Zahra, 2019, Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis, Sci. Rep., 9, 10.1038/s41598-019-48053-z